HK1150061A1 - 抗體及其應用 - Google Patents

抗體及其應用

Info

Publication number
HK1150061A1
HK1150061A1 HK11104163.0A HK11104163A HK1150061A1 HK 1150061 A1 HK1150061 A1 HK 1150061A1 HK 11104163 A HK11104163 A HK 11104163A HK 1150061 A1 HK1150061 A1 HK 1150061A1
Authority
HK
Hong Kong
Prior art keywords
antibody
Prior art date
Application number
HK11104163.0A
Other languages
English (en)
Inventor
星美奈子
佐藤道夫
井手野祥次
内藤幸嗣
保理江智
野田宗宏
堀井肇
Original Assignee
道健康生活醫藥株式會社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 道健康生活醫藥株式會社 filed Critical 道健康生活醫藥株式會社
Publication of HK1150061A1 publication Critical patent/HK1150061A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Psychiatry (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HK11104163.0A 2007-10-29 2011-04-26 抗體及其應用 HK1150061A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007280187 2007-10-29
PCT/JP2008/069696 WO2009057664A1 (ja) 2007-10-29 2008-10-29 抗体及びその利用

Publications (1)

Publication Number Publication Date
HK1150061A1 true HK1150061A1 (zh) 2011-10-28

Family

ID=40591051

Family Applications (2)

Application Number Title Priority Date Filing Date
HK11104163.0A HK1150061A1 (zh) 2007-10-29 2011-04-26 抗體及其應用
HK15103635.8A HK1203206A1 (zh) 2007-10-29 2015-04-14 抗體及其應用

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK15103635.8A HK1203206A1 (zh) 2007-10-29 2015-04-14 抗體及其應用

Country Status (6)

Country Link
US (1) US8445649B2 (zh)
EP (1) EP2224000B1 (zh)
JP (3) JP5185946B2 (zh)
CN (2) CN104098695B (zh)
HK (2) HK1150061A1 (zh)
WO (1) WO2009057664A1 (zh)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104744591B (zh) * 2010-04-15 2022-09-27 Abbvie德国有限责任两合公司 β淀粉样蛋白结合蛋白
WO2012104824A1 (en) * 2011-02-04 2012-08-09 Ecole polytechnique fédérale de Lausanne (EPFL) Therapeutic antibodies targeting app-c99
AR085302A1 (es) 2011-02-24 2013-09-18 Sanofi Sa Metodo de produccion de anticuerpos sialilados
EP2796464B1 (en) * 2011-12-22 2016-10-26 TAO Health Life Pharma Co., Ltd. Method for producing synthetic amylospheroid
JP2019038806A (ja) * 2011-12-29 2019-03-14 Ｔａｏヘルスライフファーマ株式会社 アミロスフェロイドが結合して成熟神経細胞死を誘発する標的分子、アミロスフェロイドが誘導する神経細胞死を抑制する方法及び物質、及びそれらの利用
JP5828461B2 (ja) * 2011-12-29 2015-12-09 Ｔａｏヘルスライフファーマ株式会社 アミロスフェロイドが結合して成熟神経細胞死を誘発する標的分子、アミロスフェロイドが誘導する神経細胞死を抑制する方法及び物質、及びそれらの利用
SI2906597T1 (sl) * 2012-10-15 2020-08-31 Medimmune Limited Protitelesa za amiloid beta
JP6582995B2 (ja) * 2014-01-21 2019-10-02 株式会社島津製作所 Ａｐｐ切断型ペプチドの測定方法
CN109072274A (zh) * 2016-04-14 2018-12-21 道健康生活医药株式会社 淀粉样蛋白球体（aspd）样结构体及医药组合物
WO2021100744A1 (ja) 2019-11-19 2021-05-27 Ｔａｏヘルスライフファーマ株式会社 アミロスフェロイド（ＡＳＰＤ）の代替物となりうるアミロイドβタンパク質（Ａβ）の架橋体、及びＡＳＰＤの分析

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US6548640B1 (en) * 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
WO1990012871A1 (en) 1989-04-14 1990-11-01 Research Foundation For Mental Hygiene, Inc. Cerebrovascular amyloid protein-specific monoclonal antibody sv17-6e10
US8173127B2 (en) * 1997-04-09 2012-05-08 Intellect Neurosciences, Inc. Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
TWI239847B (en) * 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
JP4227275B2 (ja) * 2000-03-09 2009-02-18 三菱化学株式会社 高い毒性を有するアミロイドβ蛋白質の調製方法
JP4317317B2 (ja) * 2000-09-28 2009-08-19 三菱化学株式会社 自己会合型アミロイドβ蛋白質
PE20020574A1 (es) 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
WO2002088306A2 (en) 2001-04-30 2002-11-07 Eli Lilly And Company Humanized antibodies
WO2004031400A2 (en) * 2002-10-01 2004-04-15 Northwestern University Amyloid beta-derived diffusible ligands (addls), addl-surrogates, addl-binding molecules, and uses thereof
CN1849139A (zh) * 2002-10-09 2006-10-18 里纳特神经系统学公司 使用针对淀粉样β肽的抗体及其组合物治疗阿尔茨海默氏病的方法
AT413945B (de) * 2003-01-14 2006-07-15 Mattner Frank Dr Impfstoff für die alzheimer-krankheit
JP4820757B2 (ja) 2004-08-11 2011-11-24 国立大学法人京都大学 抗体及びその利用
BRPI0516674A (pt) * 2004-10-28 2008-09-16 Sanko Junyaku Kk método de análise de mal de alzheimer e reagente de diagnóstico
CN101555477B (zh) * 2009-04-22 2011-04-20 北京交通大学 抗人淀粉样蛋白单克隆抗体重轻链可变区基因及其应用

Also Published As

Publication number Publication date
JPWO2009057664A1 (ja) 2011-03-10
WO2009057664A1 (ja) 2009-05-07
CN104098695B (zh) 2018-09-07
CN104098695A (zh) 2014-10-15
JP2013135667A (ja) 2013-07-11
CN101878301B (zh) 2014-08-20
CN101878301A (zh) 2010-11-03
EP2224000A1 (en) 2010-09-01
JP5185946B2 (ja) 2013-04-17
HK1203206A1 (zh) 2015-10-23
EP2224000B1 (en) 2020-05-13
JP6128535B2 (ja) 2017-05-17
US8445649B2 (en) 2013-05-21
EP2224000A4 (en) 2012-06-27
US20100297662A1 (en) 2010-11-25
JP2015221796A (ja) 2015-12-10

Similar Documents

Publication Publication Date Title
HRP20180596T1 (hr) PROTUTIJELA PROTIV Sp35 I NJIHOVA UPOTREBA
EP2236604A4 (en) ANTI-NR10 ANTIBODIES AND USE THEREOF
SI2099826T1 (sl) Anti-beta-amiloidno protitelo in njegova uporaba
HK1142341A1 (en) Anti-hepcidin antibodies and uses thereof
IL200012A0 (en) Anti-robo4 antibodies and uses therefor
ZA200900351B (en) Prlr-specific antibody and uses thereof
ZA200810311B (en) Anti-NKG2A antibodies and uses thereof
IL209309A0 (en) Anti-fn14 antibodies and uses thereof
IL216731A (en) And antibodies against p95 – her2 and their uses
EP2354161A4 (en) ANTI-NR10 ANTIBODIES AND CORRESPONDING USE
HK1203206A1 (zh) 抗體及其應用
IL201034A0 (en) Novel human anti-r7v antibodies and uses thereof
SI2354161T1 (sl) Anti-NR10 protitelo in njegova uporaba
EP2388320A4 (en) ANTI-HS6ST2 ANTIBODIES AND USE THEREOF
EP2128249A4 (en) ZINC OXIDE FIXING ANTIBODIES AND USE THEREOF
EP2322610A4 (en) ANTI-CLCP1 HUMAN ANTIBODIES AND USE THEREOF
EP2133326A4 (en) NEW PSEUDOGLYCOLIPID AND ITS USE
GB0812277D0 (en) Antibody and uses thereof
ZA200905136B (en) Anti-robo4 antibodies and uses therefor

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20211031